Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,900 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Aikata H. Ando Y, et al. Among authors: kodama k. Liver Cancer. 2022 Nov 29;12(3):251-261. doi: 10.1159/000528145. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37601981 Free PMC article.
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Among authors: kodama k. Cancers (Basel). 2021 Aug 5;13(16):3958. doi: 10.3390/cancers13163958. Cancers (Basel). 2021. PMID: 34439111 Free PMC article.
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S, Kawaoka T, Johira Y, Miura R, Kosaka M, Shirane Y, Murakami S, Amioka K, Naruto K, Ando Y, Kosaka Y, Yamaoka K, Kodama K, Uchikawa S, Fujino H, Ohno A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori K, Arihiro K, Kuroda S, Kobayashi T, Ohdan H, Aikata H. Yano S, et al. Among authors: kodama k. Medicine (Baltimore). 2021 Oct 22;100(42):e27576. doi: 10.1097/MD.0000000000027576. Medicine (Baltimore). 2021. PMID: 34678902 Free PMC article.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Murakami S, Yano S, Naruto K, Ando Y, Kosaka Y, Fujii Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Moriya T, Naeshiro N, Nonaka M, Hyogo H, Aisaka Y, Azakami T, Hiramatsu A, Aikata H. Amioka K, et al. Among authors: kodama k. Cancers (Basel). 2022 Jan 10;14(2):320. doi: 10.3390/cancers14020320. Cancers (Basel). 2022. PMID: 35053484 Free PMC article.
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Johira Y, Kawaoka T, Kosaka M, Shirane Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Ando Y, Kosaka Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Sentani K, Oue N, Arihiro K, Kuroda S, Kobayashi T, Ohdan H, Chayama K, Aikata H. Johira Y, et al. Among authors: kodama k. Liver Cancer. 2021 Nov 15;11(2):174-177. doi: 10.1159/000520898. eCollection 2022 Apr. Liver Cancer. 2021. PMID: 35634428 Free PMC article. No abstract available.
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Kosaka Y, Kawaoka T, Kosaka M, Shirane Y, Miura R, Murakami S, Johira Y, Yano S, Amioka K, Naruto K, Ando Y, Kodama K, Uchikawa S, Fujino H, Ohno A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Aikata H. Kosaka Y, et al. Among authors: kodama k. Intern Med. 2023 Jun 15;62(12):1771-1774. doi: 10.2169/internalmedicine.9581-22. Epub 2022 Nov 2. Intern Med. 2023. PMID: 36328580 Free PMC article.
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice.
Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Uchikawa S, et al. Among authors: kodama k. Hepatol Res. 2018 Sep;48(10):814-820. doi: 10.1111/hepr.13180. Epub 2018 May 27. Hepatol Res. 2018. PMID: 29682855
Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma.
Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K. Kawaoka T, et al. Among authors: kodama k. Hepatol Res. 2018 Dec;48(13):1118-1130. doi: 10.1111/hepr.13232. Epub 2018 Aug 23. Hepatol Res. 2018. PMID: 30030881
Early experience of seven hepatocellular carcinoma cases treated with regorafenib.
Uchikawa S, Kawaoka T, Aikata H, Kodama K, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Uchikawa S, et al. Among authors: kodama k. Clin Case Rep. 2018 Oct 11;6(11):2217-2223. doi: 10.1002/ccr3.1791. eCollection 2018 Nov. Clin Case Rep. 2018. PMID: 30455925 Free PMC article.
1,900 results